Tarsus Pharmaceuticals (TARS) Competitors

Roivant Sciences (NASDAQ:ROIV) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Which has stronger valuation and earnings, ROIV or TARS?

Tarsus Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	278.13	-$171.98M	-$0.70	-16.98
Tarsus Pharmaceuticals	$182.95M	12.55	-$115.55M	-$2.33	-23.35

Do institutionals and insiders have more ownership in ROIV or TARS?

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, ROIV or TARS?

Roivant Sciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Is ROIV or TARS more profitable?

Tarsus Pharmaceuticals has a net margin of -31.13% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-2,111.79%	-15.90%	-14.95%
Tarsus Pharmaceuticals	-31.13%	-32.36%	-21.04%

Does the media refer more to ROIV or TARS?

In the previous week, Tarsus Pharmaceuticals had 13 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Tarsus Pharmaceuticals and 10 mentions for Roivant Sciences. Tarsus Pharmaceuticals' average media sentiment score of 0.80 beat Roivant Sciences' score of -0.08 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ROIV or TARS?

Roivant Sciences currently has a consensus target price of $16.50, indicating a potential upside of 38.83%. Tarsus Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 22.53%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.25
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Roivant Sciences beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.